Skip to main navigation menu Skip to main content Skip to site footer


Vol. 150 No. 1920 (2020)

Early off-label treatment during pandemics? A dilemma

  • Jan A. Roth
  • Tala Ballouz
  • Roger D. Kouyos
  • Manuel Battegay
Cite this as:
Swiss Med Wkly. 2020;150:w20281


  1. Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.
  2. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.
  3. Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.
  4. Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.
  5. Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.

Most read articles by the same author(s)

1 2 3 > >>